We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Adalimumab as a cause of kidney injury in patients with Crohn's disease.
- Authors
Skoczyński, Krzysztof; Koziej, Jan; Szymańska, Sylwia; Obrycki, Łukasz; Grenda, Ryszard; Litwin, Mieczysław
- Abstract
Introduction: Adalimumab (ADM) is a recombinant human monoclonal antibody (anti-TNFα) used to treat inflammatory bowel diseases. It can cause kidney injury (KI). Case diagnosis/treatment: We describe two pediatric patients with Crohn's disease (CD) in whom ADM therapy was associated with kidney injury (KI). The drug was discontinued in both cases. For the first patient, changes were irreversible despite intensive glucocorticosteroid (GCS) therapy. For the second patient, discontinuation of ADM led to an improvement in kidney function. Conclusions: Due to the risk of KI in patients undergoing ADM therapy, careful assessment of kidney function and early specialist referral are required. Timely withdrawal of ADM can significantly reduce kidney damage, but in some cases, the kidney damage can be irreversible.
- Subjects
DRUG allergy; KIDNEY function tests; BIOPSY; CROHN'S disease; DRUG side effects; TERMINATION of treatment; ACUTE kidney failure; ULTRASONIC imaging; PEDIATRICS; ADALIMUMAB; URINALYSIS; DISEASE risk factors
- Publication
Pediatric Nephrology, 2024, Vol 39, Issue 8, p2359
- ISSN
0931-041X
- Publication type
Article
- DOI
10.1007/s00467-024-06338-0